In Reply We read with attention comments from Bianco et al regarding the ENIGM (Enquête Nationale sur I’Introduction du Fingolimod en Relais au Natalizumab) study.
In our statistical analysis, the main outcome was the presence of clinical disease reactivation (occurrence of at least 1 relapse) during the switching period. We first analyzed the washout then the fingolimod initiation period during a 6-month follow-up.1
Cohen M, Lebrun C. Moving to Fingolimod From Natalizumab in Multiple Sclerosis—Reply. JAMA Neurol. 2014;71(7):925. doi:10.1001/jamaneurol.2014.1138